Meeting
2015 Genitourinary Cancers Symposium
Potential synergistic effects of bisphosphonates with sorafenib on renal cell carcinoma with bone metastases.
Authors
Ye Ding-Wei
Department of Urology, Fudan University, Shanghai Cancer Center, Shanghai, China
Ye Ding-Wei , Zhang Hai-Lang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 496)
DOI
10.1200/jco.2015.33.7_suppl.496
Abstract #
496
Poster Bd #
G24
Abstract Disclosures
Similar Posters
Poster
2011 Genitourinary Cancers Symposium
Brain metastasis in metastatic renal cell carcinoma: Predictive factors of occurrence and survival with or without antiangiogenic therapy.
First Author: Marie Vanhuyse
Poster
2019 ASCO Annual Meeting
Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.
First Author: Darya Kizub
Poster
2018 Genitourinary Cancers Symposium
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
First Author: Sergio Bracarda
Poster
2012 ASCO Annual Meeting
Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
First Author: Avivit Peer